DsRNA (double-stranded ribonucleic acid) as well as application and preparation method thereof
By designing specific modified double-stranded ribonucleic acid (dsRNA) and combining targeted ligands, the problem of poor effectiveness of existing hypertensive treatment drugs is solved, efficient delivery of dsRNA and targeted reduction of AGT genes is achieved, and new Methods for treating hypertension and related diseases.
Patent Information
- Application Number
- CN202410602382.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-22
AI Technical Summary
There are many existing hypertensive therapeutic drugs that have high co-use rates, and their compliance and side effects have increased, resulting in poor blood pressure control effects, and most unacceptable proteins cannot be targeted by conventional drugs. RNA interference technology has important drug development prospects but needs to be effective. Deliver dsRNA into the body.
A double-stranded ribonucleic acid (dsRNA) is designed that contains sense and antisense strands, specific nucleotide modifications and chemical modifications, combining targeted ligands to improve intracellular delivery efficiency, including specifically 2'-fluoro and 2 '-methoxy modified nucleotides, and phosphate groups modified, are used to target the AGT gene to reduce its expression.
The efficient delivery and targeting of dsRNAs was achieved, significantly reducing the expression level of AGT, and providing a new potential drug strategy for the treatment of hypertension and related diseases.
Smart Images

Figure BDA0004840982230000061 
Figure BDA0004840982230000091 
Figure BDA0004840982230000092
Abstract
Description
[0001] The present disclosure claims the priority of Chinese patent application 202310569702.0 filed on May 19, 2023 and Chinese patent application 202310591767.5 filed on May 24, 2023, and the present disclosure cites the full text of the above-mentioned Chinese patent applications. Technical Field
[0002] The present disclosure relates to the technical field of using dsRNA to reduce the expression of target RNA and treat related diseases. Specifically, the present disclosure relates to the preparation and application of dsRNA. Background Art
[0003] AGT is also known as SERPINA8 or ANHU. AGT is encoded by the AGT gene and is mainly produced by the liver. It is a rate-limiting substrate of the renin-angiotensin system (RAS) and a precursor of angiotensin peptide. Under the action of active renin in plasma, AGT is split into angiotensin I, which is subsequently converted into angiotensin II by the action of circulating and locally expressed angiotensin-converting enzyme (ACE). Angiotensin II is the most important bioactive substance in the renin-angiotensin-aldosterone system (RAAS). It binds to the angiotensin II type 1 receptor (AT1R), causing arterial vasoconstriction and adrenal cortical aldosterone secretion, and therefore plays a key role in the body's blood pressure regulation. When angiotensin II is overproduced or AT1R is overstimulated, RAAS system dysfunction will cause hypertension. Many studies have shown that the polymorphism of the AGT gene is closely related to the body's ability to regulate blood pressure, and association studies in the Han Chinese population have shown that the AGT M235T site polymorphism is associated with the occurrence of essential hypertension (ER).
[0004] Hypertension is a common cardiovascular disease worldwide, with a global prevalence of 10% to 20%. It can lead to complications of cerebrovascular, cardiac and renal diseases and is a major risk factor for various diseases, disorders and conditions (such as stroke, coronary heart disease, chronic kidney disease, myocardial infarction, heart failure, aneurysm, peripheral arterial disease, heart damage and other cardiovascular-related diseases). Currently, there are five main types of drugs for the treatment of hypertension, including diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Although there are many types of antihypertensive drugs that can be used to treat hypertension, more than two-thirds of the subjects cannot be controlled with one antihypertensive drug and need two or more different types of antihypertensive drugs. Since compliance and side effects increase with increased medication, this further reduces the number of subjects with controlled blood pressure.
[0005] RNA interference (RNAi) is an effective way to silence gene expression. According to statistics, among the disease-related proteins in the human body, more than 80% of the proteins cannot be targeted by currently conventional small molecule drugs and biological macromolecule preparations, and are undruggable proteins. Using RNA interference technology, appropriate dsRNA can be designed based on the mRNA encoding these proteins, specifically targeting the target mRNA and degrading the target mRNA, thereby inhibiting the production of related proteins. Therefore, dsRNA has a very important prospect for drug development. However, to achieve the RNA interference effect for therapeutic purposes in vivo, it is necessary to deliver dsRNA molecules to specific cells in the body.
[0006] It is an effective way to deliver drugs by conjugating dsRNA with a targeting ligand and using the molecular structure of the targeting ligand and the receptor on the cell membrane surface to enter the cell through internalization. For example, the asialoglycoprotein receptor (ASGPR) is a receptor specifically expressed by hepatocytes. It has high abundance on the surface of hepatocytes and is characterized by rapid intracellular and extracellular conversion. Monosaccharide and polysaccharide molecules such as galactose, galactosamine, and N-acetylgalactosamine have high affinity for ASGPR. Summary of the invention
[0007] In a first aspect, the present disclosure provides a double-stranded ribonucleic acid (dsRNA), comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise consecutive nucleotides in the direction from the 5' end to the 3' end, wherein the nucleotides at positions 7, 8 and 9 of the sense strand are 2'-fluoro-modified nucleotides, the nucleotide at position 5 is independently a 2'-methoxy-modified nucleotide or a 2'-fluoro-modified nucleotide, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides; the nucleotides at positions 2 and 14 of the antisense strand are 2'-fluoro-modified nucleotides, the nucleotides at positions 4, 6, 8, 9, 10, 12, 16 and 18 are independently 2'-methoxy-modified nucleotides or 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides; the number of 2'-fluoro-modified nucleotides in the antisense strand is 2-7. In some embodiments, the nucleotides at positions 7, 8, and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides; the nucleotides at positions 2, 6, 12, 14, and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides;
[0008] At least one nucleotide position from position 2 to position 8 of the antisense strand comprises a chemical modification represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof:
[0009] The chemical modification represented by the formula (I) is selected from any of the following structures:
[0010] B is a base when the nucleoside in at least one of the 2nd to 8th positions in the 5' region of the antisense strand is unmodified;
[0011] The dsRNA also includes a ligand conjugated thereto, wherein the ligand has the following structure or a pharmaceutically acceptable salt thereof,
[0012] In some embodiments, the nucleoside comprising the chemical modification represented by formula (I), its tautomer or its pharmaceutically acceptable salt is located at position 5, 6 or 7 of the 5' region of the antisense strand. In some embodiments, it is located at position 7 of the 5' region of the antisense strand.
[0013] In some embodiments, when the chemical modification represented by formula (I), its tautomer or its pharmaceutically acceptable salt is modified at position 5, 6 or 7 of its 5' region, B is selected from adenine, guanine, 2,6-diaminopurine, 6-dimethylaminopurine, 2-aminopurine, cytosine, uracil, thymine, indole, 5-nitroindole and 3-nitropyrrole.
[0014] In some embodiments, B is the same as the base when the nucleoside at position 5, 6, or 7 of the 5' region of the antisense strand is unmodified.
[0015] In yet another aspect, the present disclosure provides a dsRNA comprising a sense strand and an antisense strand:
[0016] In some embodiments, the antisense strand is at least partially reverse complementary to the target sequence; in some embodiments, there are no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 mismatch between the antisense strand and the target sequence; in some embodiments, the antisense strand is completely reverse complementary to the target sequence.
[0017] In some embodiments, the sense strand and the antisense strand are at least partially reverse complementary to form a double-stranded region; in some embodiments, there are no more than 5, no more than 4, no more than 3, no more than 2, no more than 1 mismatch between the sense strand and the antisense strand; in some embodiments, the sense strand and the antisense strand are completely reverse complementary.
[0018] In some embodiments, the sense strand and antisense strand each independently have 16 to 35, 16 to 34, 17 to 34, 17 to 33, 18 to 33, 18 to 32, 18 to 31, 18 to 30, 18 to 29, 18 to 28, 18 to 27, 18 to 26, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, or 19 to 23 nucleotides (e.g., 19, 20, 21, 22, 23 nucleotides).
[0019] In some embodiments, the sense strand and antisense strand are the same or different in length, the sense strand is 19-23 nucleotides in length, and the antisense strand is 19-26 nucleotides in length. In some embodiments, the length ratio of the sense strand to the antisense strand can be 19 / 19, 19 / 20, 19 / 21, 19 / 22, 19 / 23, 19 / 24, 19 / 25, 19 / 26, 20 / 19, 20 / 20, 20 / 21, 20 / 22, 20 / 23, 20 / 24, 20 / 25, 20 / 26, 21 / 20, 21 / 21, 21 / 22, 21 / 23, 21 / 24, 21 / 25, 21 / 26, 22 / 20, 22 / 21, 22 / 22, 22 / 23, 22 / 24, 22 / 25, 22 / 26, 23 / 20, 23 / 21, 23 / 22, 23 / 23, 23 / 24, 23 / 25, or 23 / 26. In some embodiments, the length ratio of the sense strand to the antisense strand is 19 / 21, 21 / 23, or 23 / 25. In some embodiments, the length ratio of the sense strand to the antisense strand is 19 / 21.
[0020] In some embodiments, the dsRNA comprises one or two blunt ends.
[0021] In some embodiments, the dsRNA comprises an overhang of 1 to 4 unpaired nucleotides, eg, 1, 2, 3, 4.
[0022] In some embodiments, the dsRNA comprises an overhang at the 3' end of the antisense strand.
[0023] In some embodiments, the sense strand and the antisense strand comprise or are nucleotide sequences as shown in the following formula:
[0024] Sense strand: 5'-N a N a N a N a XN a N b N b N b N a N a N a N a N a N a N a N a N a N a -3';
[0025] Antisense strand: 5'-N a 'N b'N a 'X'N a 'X'W'X'X'X'N a 'X'N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a '-3';
[0026] Where each X is independently N a or N b , each X' is independently N a ' or N b ';N a and N a ' is a 2'-methoxy modified nucleoside, N b and N b ' is a 2'-fluoro modified nucleoside, and two adjacent nucleosides are connected by a phosphate bond or a phosphate bond with a modified group;
[0027] In some embodiments, the sense strand and the antisense strand comprise or are nucleotide sequences as shown in the following formula:
[0028] Sense strand: 5'-N a N a N a N a N a N a N b N b N b N a N a N a N a N a N a N a N a N a N a -3';
[0029] Antisense strand: 5'-N a 'N b 'N a 'X'N a 'X'W'X'X'X'N a 'X'N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a '-3';
[0030] Where each X' is independently N a ' or N b ';N a and N a ' is a 2'-methoxy modified nucleoside, N b and N b ' is a 2'-fluoro modified nucleoside, and two adjacent nucleosides are connected by a phosphate bond or a phosphate bond with a modified group;
[0031] W' represents a 2'-methoxy-modified nucleotide or a nucleotide comprising the chemical modification represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof.
[0032] In some embodiments, the sense strand comprises or is a nucleotide sequence as shown in the following formula:
[0033] 5'-N a N a N a N a XN a N b N b N b N a N a N a N a N a N a N a N a N a N a -3';
[0034] Where X is N a or N b ; N a is a 2'-methoxy-modified nucleoside, N b It is a 2'-fluoro modified nucleoside, and two adjacent nucleosides are connected by a phosphate bond or a phosphate bond with a modified group.
[0035] In some embodiments, the sense strand comprises or is a nucleotide sequence as shown in the following formula:
[0036] 5'-N a N a N a N a N a N a N b N b N b N a N a N a Na N a N a N a N a N a N a -3';
[0037] Among them, N a is a 2'-methoxy-modified nucleoside, N b It is a 2'-fluoro modified nucleoside, and two adjacent nucleosides are connected by a phosphate bond or a phosphate bond with a modified group.
[0038] In some embodiments, the antisense strand comprises or is a nucleotide sequence as shown in the following formula:
[0039] 5'-N a 'N b 'N a 'X'N a 'X'W'X'X'X'N a 'X'N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a '-3';
[0040] Where each X' is independently N a ' or N b ';N a ' is a 2'-methoxy modified nucleoside, N b ' is a 2'-fluoro modified nucleoside
[0041] W' represents a 2'-methoxy modified nucleoside or a nucleoside comprising the chemical modification represented by formula (I), its tautomer or a pharmaceutically acceptable salt thereof, wherein two adjacent nucleosides in the above formula are linked by a phosphate bond or a phosphate bond having a modified group.
[0042] In some embodiments, W' in the above nucleotide sequence represents a 2'-methoxy modified nucleoside.
[0043] In some embodiments, W' in the above nucleotide sequence represents a nucleoside comprising a chemical modification represented by formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, W' has the following structure:
[0044] In some embodiments, the chemical modification represented by formula (I) is selected from:
[0045] Wherein: B is selected from guanine, adenine, cytosine and uracil; in some specific embodiments, B is the same as the base of the nucleoside at the corresponding position of the antisense strand when it is not modified. In some embodiments, the chemical modification shown in formula (I) and the adjacent nucleoside or chemical modification are connected by a phosphate bond or a thiophosphate bond.
[0046] In some embodiments, the antisense strand comprises or is a nucleotide sequence as shown in the following formula:
[0047] 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a 'N a 'N a '-3';
[0048] 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N a 'N b 'N a 'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a '-3';
[0049] 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N a 'N a 'Na ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’;
[0050] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’;
[0051] 5’-N a ’N b ’N a ’N b ’N a ’N b ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’;
[0052] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N b’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’;
[0053] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’;
[0054] 5’-N a ’N b ’N a ’N a ’N a ’N a ’W’N b ’N b ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’;
[0055] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’Na ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’;
[0056] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’;
[0057] 5’-N a ’N b ’N a ’N a ’N a ’N a ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’; or,
[0058] 5’-N a ’N b ’N a ’N a ’N a ’N a ’W’N a ’N a'N a 'N a 'N a 'N a 'N b 'N a 'N a 'N a 'N a 'N a 'N a 'N a '-3';
[0059] Among them, N a ' is a 2'-methoxy modified nucleoside, N b ' is a 2'-fluoro-modified nucleoside;
[0060] W' represents a 2'-methoxy modified nucleoside or a nucleoside comprising a chemical modification represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof.
[0061] In some embodiments, W' represents a 2'-methoxy modified nucleoside.
[0062] In some embodiments, W' represents a nucleotide comprising a chemical modification as shown in formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof, and in some embodiments W' has the following structure:
[0063]
[0064] In some embodiments, the chemical modification represented by formula (I) is selected from:
[0065] Wherein: B is selected from guanine, adenine, cytosine and uracil; in some specific embodiments, B is the same as the base of the antisense strand when the 7th nucleotide in the 5' region is not modified.
[0066] In some embodiments, at least one phosphate group in the sense strand and / or antisense strand is a phosphate group with a modification group, and the modification group allows the dsRNA to have increased stability in a biological sample or environment; in some embodiments, the phosphate group with a modification group is a thiophosphate group. In some embodiments, the phosphate group with a modification group is a thiophosphate diester group.
[0067] In some embodiments, the phosphorothioate diester group is present in at least one of the following positions:
[0068] between the first nucleotide and the second nucleotide at the 5' end of the sense strand;
[0069] between the second nucleotide and the third nucleotide at the 5' end of the sense strand;
[0070] Between the first nucleotide and the second nucleotide at the 5' end of the antisense strand;
[0071] Between the second nucleotide and the third nucleotide at the 5' end of the antisense strand;
[0072] between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and
[0073] Between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
[0074] In some embodiments, the sense strand and / or antisense strand comprises a plurality of phosphorothioate diester groups, wherein the phosphorothioate diester groups are present in:
[0075] between the first nucleotide and the second nucleotide at the 5' end of the sense strand; and,
[0076] between the second nucleotide and the third nucleotide at the 5' end of the sense strand; and,
[0077] between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; and,
[0078] between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; and,
[0079] between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and,
[0080] Between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
[0081] In some embodiments, the sense strand comprises a nucleotide sequence as shown in the following formula:
[0082] 5'-NmsNmsNmNmNfNmNfNfNfNmNmNmNmNmNmNmNmNmNmNm-3', or, 5'-NmsNmsNmNmNmNmNfNfNfNmNmNmNmNmNmNmNmNmNmNm-3',
[0083] Wherein, Nm represents any 2'-methoxy modified nucleoside, such as 2'-methoxy modified C, G, U, A; Nf represents any 2'-fluoro modified nucleoside, such as 2'-fluoro modified C, G, U, A;
[0084] When the lowercase letter s is in the middle, it means that the two nucleosides adjacent to the letter s are connected by a thiophosphate diester group.
[0085] In some embodiments, the sense strand comprises a nucleotide sequence as shown in the following formula:
[0086] 5'-NmsNmsNmNmNmNmNfNfNfNmNmNmNmNmNmNmNmNmNmNm-3',
[0087] Wherein, Nm represents any 2'-methoxy modified nucleoside, such as 2'-methoxy modified C, G, U, A; Nf represents any 2'-fluoro modified nucleoside, such as 2'-fluoro modified C, G, U, A;
[0088] When the lowercase letter s is in the middle, it means that the two nucleotides adjacent to the letter s are connected by a phosphorothioate diester group.
[0089] In some embodiments, the antisense strand comprises or is a nucleotide sequence as shown in the following formula: 5'-Nm'sNf'sNm'Nf'Nm'Nf'W'Nm'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nm'Nm'sN m'sNm'-3';
[0090] 5'-Nm'sNf'sNm'Nf'Nm'Nf'W'Nm'Nm'Nf'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nf'Nm'sN m'sNm'-3';
[0091] 5'-Nm'sNf'sNm'Nf'Nm'Nf'W'Nm'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nf'Nm'sN m'sNm'-3';
[0092] 5'-Nm'sNf'sNm'Nm'Nm'Nf'W'Nm'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nf'Nm'sN m'sNm'-3';
[0093] 5'-Nm'sNf'sNm'Nf'Nm'Nf'W'Nm'Nm'Nm'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nm'Nm'sNm'sNm'-3';
[0094] 5'-Nm'sNf'sNm'Nm'Nm'Nf'W'Nm'Nm'Nf'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nm'Nm'sNm'sNm'-3';
[0095] 5'-Nm'sNf'sNm'Nm'Nm'Nf'W'Nm'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nf'Nm'Nm'Nm'sNm'sNm'-3';
[0096] 5'-Nm'sNf'sNm'Nm'Nm'Nm'W'Nf'Nf'Nm'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nm'Nm'sNm'sNm'-3';
[0097] 5'-Nm'sNf'sNm'Nm'Nm'Nf'W'Nm'Nm'Nm'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nm'Nm'sNm'sNm'-3';
[0098] 5'-Nm'sNf'sNm'Nm'Nm'Nf'W'Nm'Nm'Nm'Nm'Nm'Nm'Nf'Nm'Nm'Nm'Nm'Nm'sNm'sNm'-3';
[0099] 5'-Nm'sNf'sNm'Nm'Nm'Nm'W'Nm'Nm'Nm'Nm'Nm'Nm'Nf'Nm'Nf'Nm'Nm'Nm'sNm'sNm'-3'; or,
[0100] 5'-Nm'sNf'sNm'Nm'Nm'Nm'W'Nm'Nm'Nm'Nm'Nm'Nm'Nf'Nm'Nm'Nm'Nm'Nm'sNm'sNm'-3';
[0101] Wherein, Nm' represents any 2'-methoxy modified nucleoside, such as 2'-methoxy modified C, G, U, A; Nf' represents any 2'-fluoro modified nucleoside, such as 2'-fluoro modified C, G, U, A;
[0102] When the lowercase letter s is in the middle, it means that the two nucleotides adjacent to the letter s on the left and right are connected by phosphorothioate diester groups. When the lowercase letter s is the first at the 3' end, it means that the terminal of the nucleotide adjacent to the left of the letter s is a phosphorothioate diester group.
[0103] W' represents a 2'-methoxy modified nucleoside or a nucleoside modified with the chemical modification represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof.
[0104] In some embodiments, W' represents a 2'-methoxy modified nucleoside.
[0105] In some embodiments, W' represents a nucleoside comprising a chemical modification as shown in formula (I), a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0106] In some embodiments, the chemical modification represented by formula (I) is selected from:
[0107] Wherein: B is selected from guanine, adenine, cytosine and uracil; in some embodiments, B is the same as the base of the antisense strand when the 7th nucleotide in the 5' region thereof is not modified;
[0108] Two adjacent nucleosides or adjacent nucleosides and chemical modifications in the above nucleotide sequence are connected via a phosphate group or a modified phosphate group.
[0109] In some embodiments, the dsRNA inhibits the expression of angiotensinogen (AGT).
[0110] In some embodiments, the sense strand comprises at least 15 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO: 15 by no more than 3 nucleotides, and / or,
[0111] The antisense strand comprises at least 19 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO:16 by no more than 3 nucleotides.
[0112] In some embodiments, the sense strand comprises or is selected from the group consisting of a nucleotide sequence of SEQ ID NO:15, and / or the antisense strand comprises or is selected from the group consisting of a nucleotide sequence of SEQ ID NO:16.
[0113] In some embodiments, the sense strand and / or antisense strand and the ligand are covalently or non-covalently linked.
[0114] In some embodiments, the 3' end and / or the 5' end of the sense strand is conjugated to the ligand.
[0115] In some embodiments, the 3' end of the sense strand is conjugated to the ligand.
[0116] In some embodiments, the ligand is connected to the end of the sense strand and / or antisense strand through a phosphate group or a thiophosphate group. In some embodiments, the ligand is connected to the end of the sense strand and / or antisense strand through a phosphodiester group or a thiophosphate group. In some embodiments, the ligand is connected to the end of the sense strand and / or antisense strand through a phosphodiester group or a thiophosphate group. In some embodiments, the ligand is connected to the end of the sense strand and / or antisense strand through a phosphodiester group. In some embodiments, the ligand is indirectly connected to the end of the sense strand and / or antisense strand through a phosphate group or a thiophosphate group. In some embodiments, the ligand is directly connected to the end of the sense strand and / or antisense strand through a phosphate group or a thiophosphate group. In some embodiments, the ligand is directly connected to the 3' end of the sense strand through a phosphate group or a thiophosphate group.
[0117] In some embodiments, the phosphate group is a phosphate monoester group or a phosphate diester group. In some embodiments, the phosphate group is a phosphate diester group. In some embodiments, the thiophosphate group is a thiophosphate monoester group or a thiophosphate diester group. In some embodiments, the thiophosphate group is a thiophosphate diester group.
[0118] In some embodiments, in order to facilitate dsRNA to enter cells, lipophilic groups such as cholesterol can be introduced at the end of the sense strand. Lipophilic groups include covalent bonds with small interfering nucleic acids, such as the introduction of cholesterol, lipoprotein, vitamin E, etc. at the end, so as to facilitate the interaction with mRNA in cells through the cell membrane composed of lipid bilayers. At the same time, dsRNA can also be modified with non-covalent bonds, such as binding phospholipid molecules, polypeptides, cationic polymers, etc. through hydrophobic bonds or ionic bonds to increase stability and biological activity.
[0119] In some embodiments, the number of the ligands includes, but is not limited to, 1, 2, 3, or 4. In some embodiments, the number of the ligands is 1.
[0120] In some embodiments, the ligand has the following structure or a pharmaceutically acceptable salt thereof:
[0121]
[0122] In some embodiments, the nucleotide sequence of the sense strand of the dsRNA comprises or is the sequence shown in SEQ ID NO: 1, and the nucleotide sequence of the antisense strand comprises or is the nucleotide sequence of any one of SEQ ID NO: 2 to SEQ ID NO: 12. In some embodiments, the sense strand of the dsRNA is the nucleotide sequence shown in SEQ ID NO: 1, and the antisense strand is the nucleotide sequence shown in SEQ ID NO: 2.
[0123] In some embodiments, the dsRNA is selected from the following structures or a pharmaceutically acceptable salt thereof:
[0124]
[0125] In some embodiments, the pharmaceutically acceptable salt may be a conventional salt in the art, including but not limited to sodium salt, potassium salt, ammonium salt, amine salt, and the like.
[0126] In some embodiments, the dsRNA is TJR101202.
[0127] In some embodiments, the dsRNA is the following structure or a pharmaceutically acceptable salt thereof:
[0128]
[0129] In some embodiments, the dsRNA is the following structure or a pharmaceutically acceptable salt thereof:
[0130]
[0131] In the above structural formula, Af = adenine 2'-F ribonucleoside; Cf = cytosine 2'-F ribonucleoside; Uf = uracil 2'-F ribonucleoside; Am = adenine 2'-OMe ribonucleoside; Cm = cytosine 2'-OMe ribonucleoside; Gf = guanine 2'-F ribonucleoside; Gm = guanine 2'-OMe ribonucleoside. Um = uracil 2'-OMe ribonucleoside; Um = uracil 2'-OMe ribonucleoside.
[0132] represents the phosphorothioate diester anion form, represents the phosphodiester anion form, represents a phosphorothioate diester group; represents a phosphodiester group;
[0133] L96 indicates
[0134] (-)hmpNA(C)
[0135] In another aspect, the present disclosure provides a pharmaceutical composition comprising the dsRNA described in the present disclosure.
[0136] In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients. Various drug delivery systems are known and can be used for the dsRNA or pharmaceutical compositions of the present disclosure, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis, constructing nucleic acids as part of retroviruses or other vectors.
[0137] In some embodiments, the pharmaceutical composition may further include a pharmaceutically acceptable excipient and / or adjuvant, which may be one or more of various preparations or compounds conventionally used in the art. For example, the pharmaceutically acceptable excipient may include at least one of a pH buffer, a protective agent, and an osmotic pressure regulator.
[0138] In some embodiments, the unit dose of the pharmaceutical composition is 0.001 mg-1000 mg.
[0139] In certain embodiments, the pharmaceutical composition contains 0.01-99.99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution, based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1-99.9% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 1%-99% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution. In certain embodiments, the pharmaceutical composition contains 2%-98% of the aforementioned compound or its pharmaceutically acceptable salt or its isotope substitution.
[0140] In certain embodiments, the pharmaceutical composition contains 0.01%-99.99% of a pharmaceutically acceptable excipient based on the total weight of the composition. In certain embodiments, the pharmaceutical composition contains 0.1%-99.9% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 0.5%-99.5% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 1%-99% of a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition contains 2%-98% of a pharmaceutically acceptable excipient.
[0141] In some embodiments, the administration of the dsRNA or pharmaceutical composition of the present disclosure is conventional, and can be administered topically (e.g., direct injection or implantation) or systemically, or can be administered orally, rectally or parenterally, wherein the parenteral route includes but is not limited to subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, transdermal administration, inhalation administration (e.g., aerosol), mucosal administration (e.g., sublingual, intranasal administration), intracranial administration, etc.
[0142] In some embodiments, the dsRNA or pharmaceutical composition provided by the present disclosure can be administered by injection, for example, intravenous, intramuscular, intradermal, subcutaneous, intraduodenal, or intraperitoneal injection.
[0143] In some embodiments, the dsRNA or pharmaceutical compositions provided by the present disclosure can be packaged in a kit.
[0144] In the present disclosure, the effective amount or effective dose of the dsRNA or pharmaceutical composition is about 0.001 mg / kg body weight to about 200 mg / kg body weight, about 0.01 mg / kg body weight to about 100 mg / kg body weight, or about 0.5 mg / kg body weight to about 50 mg / kg body weight.
[0145] In another aspect, the present disclosure provides a use of the dsRNA described in the present disclosure or the pharmaceutical composition described in the present disclosure in preparing a drug.
[0146] In some embodiments, the drug can be used to prevent and / or treat hypertension, cardiovascular disease or hepatic disease. In some embodiments, the drug can be used to prevent and / or treat critical hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, hypertension associated with low plasma renin activity or plasma renin concentration, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, unstable hypertension, hypertensive heart disease, hypertensive nephropathy, atherosclerosis, Atherosclerosis, vascular disease, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, coarctation of the aorta, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, valvular heart disease, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth retardation (IUGR), fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), glucose intolerance, type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), or metabolic syndrome.
[0147] In some embodiments, the drug can be used to prevent and / or treat diseases associated with AGT gene expression. In some embodiments, the disease associated with AGT gene expression may be hypertension, cardiovascular disease or hepatopathological disease. In some embodiments, the disease may be critical hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, refractory hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, hypertension associated with low plasma renin activity or plasma renin concentration, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, unstable hypertension, hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis , vascular disease, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, aortic coarctation, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, valvular heart disease, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth retardation (IUGR), fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), glucose intolerance, type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), or metabolic syndrome.
[0148] In some embodiments, the effective amount or effective dose of the dsRNA or pharmaceutical composition is about 0.001 mg / kg body weight to about 200 mg / kg body weight, about 0.01 mg / kg body weight to about 100 mg / kg body weight, or about 0.5 mg / kg body weight to about 50 mg / kg body weight.
[0149] In another aspect, the present disclosure provides a method for preventing and / or treating a disease, comprising administering an effective amount or an effective dose of the dsRNA of the present disclosure or the pharmaceutical composition of the present disclosure to a subject.
[0150] In some embodiments, the disease may be hypertension, cardiovascular disease or hepatic disease. In some embodiments, the disease may be hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, hypertension associated with low plasma renin activity or plasma renin concentration, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, unstable hypertension, hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, Vascular disease, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, coarctation of the aorta, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, valvular heart disease, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth retardation (IUGR), fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), glucose intolerance, type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), or metabolic syndrome.
[0151] In some embodiments, the disease may be a disease associated with AGT gene expression. In some embodiments, the disease associated with AGT gene expression may be hypertension, cardiovascular disease or hepatic disease. In some embodiments, the disease may be critical hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, hypertension associated with low plasma renin activity or plasma renin concentration, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, unstable hypertension, hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis , vascular disease, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, aortic coarctation, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, valvular heart disease, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth retardation (IUGR), fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), glucose intolerance, type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), or metabolic syndrome.
[0152] In another aspect, the present disclosure provides a method for silencing a target gene or its mRNA in a cell in vivo or in vitro, comprising the step of introducing the dsRNA of the present disclosure or the pharmaceutical composition of the present disclosure into the cell.
[0153] In some embodiments, the target gene is AGT.
[0154] In another aspect, the present disclosure provides a method for inhibiting the expression of a target gene or its mRNA, comprising administering an effective amount or an effective dose of the dsRNA of the present disclosure or the pharmaceutical composition of the present disclosure to a subject.
[0155] In some embodiments, the target gene is AGT.
[0156] The dsRNA or pharmaceutical composition disclosed herein can reduce the expression level of a target gene or its mRNA in an object such as a cell, a cell population, a tissue or a subject, including: administering a therapeutically effective amount of the dsRNA or pharmaceutical composition described herein to the subject, thereby inhibiting the expression of the target gene or its mRNA in the subject.
[0157] In some embodiments, the subject has been previously identified as having pathological upregulation of the target gene or its mRNA in a targeted cell, cell population, tissue, or subject.
[0158] In another aspect, the present disclosure provides a method for delivering an oligonucleotide to the liver, comprising administering to a subject an effective amount or an effective dose of the dsRNA of the present disclosure or the pharmaceutical composition of the present disclosure.
[0159] In another aspect, the present disclosure provides an RNA interference (RNAi) agent comprising the dsRNA described in the present disclosure or the pharmaceutical composition described in the present disclosure.
[0160] In another aspect, the present disclosure further provides a cell comprising the dsRNA of the present disclosure or the pharmaceutical composition of the present disclosure.
[0161] In another aspect, the present disclosure further provides a kit comprising the dsRNA described in the present disclosure or the pharmaceutical composition described in the present disclosure.
[0162] In some embodiments, the dsRNA of the present disclosure is selected from siRNA.
[0163] In the present disclosure, when the dsRNA or pharmaceutical composition of the present disclosure is contacted with a cell expressing the target gene, the dsRNA or pharmaceutical composition of the present disclosure will inhibit the expression of the target gene by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, as determined by, for example, psiCHECK activity screening and luciferase reporter gene assay, other methods such as PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, such as Western Blot or flow cytometry.
[0164] In the present disclosure, when the dsRNA or pharmaceutical composition of the present disclosure is contacted with cells expressing the target gene, the residual expression percentage of the target gene mRNA caused by the dsRNA or pharmaceutical composition of the present disclosure is not higher than 99%, not higher than 95%, not higher than 90%, not higher than 85%, not higher than 80%, not higher than 75%, not higher than 70%, not higher than 65%, not higher than 60%, not higher than 55%, not higher than 50%, not higher than 45%, not higher than 40%, not higher than 35%, not higher than 30%, not higher than 25%, not higher than 20%, not higher than 15%, or not higher than 10%, as determined by, for example, psiCHECK activity screening and luciferase reporter gene assay, other methods such as PCR or branched DNA (bDNA) based methods, or protein-based methods such as immunofluorescence analysis, such as Western Blot or flow cytometry.
[0165] In the present disclosure, when the dsRNA or pharmaceutical composition of the present disclosure is contacted with cells expressing the target gene, the dsRNA reduces the off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or at least 75% while maintaining the target activity, as determined by, for example, psiCHECK activity screening and luciferase reporter gene assay, other methods such as PCR or branched DNA (bDNA)-based methods, or protein-based methods such as immunofluorescence analysis, such as Western Blot, or flow cytometry.
[0166] In the present disclosure, when the dsRNA or pharmaceutical composition of the present disclosure is contacted with cells expressing the target gene, the dsRNA reduces the target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or at least 75%, as determined by, for example, psiCHECK activity screening and luciferase reporter gene assay, other methods such as PCR or branched DNA (bDNA) based methods, or protein-based methods such as immunofluorescence analysis, such as Western Blot, or flow cytometry.
[0167] In the present disclosure, when the dsRNA or pharmaceutical composition of the present disclosure is contacted with a cell expressing a target gene, the dsRNA increases the target activity by at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% or at least 80%, while reducing the off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or at least 75%, as determined by, for example, psiCHECK activity screening and luciferase reporter gene assay, other methods such as PCR or branched DNA (bDNA) based methods, or protein based methods such as immunofluorescence analysis, such as Western Blot, or flow cytometry.
[0168] The compounds of the present disclosure may exist in specific geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, all of which are within the scope of the present disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present disclosure. The compounds of the present disclosure containing asymmetric carbon atoms may be isolated in optically pure form or in racemic form. Optically pure forms may be resolved from racemic mixtures or synthesized by using chiral raw materials or chiral reagents.
[0169] Optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is usually accomplished by using chromatography, which uses a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamates are generated from amines).
[0170] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if there are chiral isomers in the chemical structure, the bond Can be or or include both and In the chemical structure of the compounds disclosed in the present invention, the bond No configuration is specified, i.e., the bond The configuration can be E-type or Z-type, or include both E and Z configurations.
[0171] In the chemical structural formula disclosed herein, One or more of any group may be attached in accordance with the scope of the invention described herein; an asterisk "*" indicates a chiral center.
[0172] Without specifying the configuration, the compounds and intermediates of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure.The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier.
[0173] All compounds in the present disclosure can be drawn as either Form A or Form B. All tautomeric forms are within the scope of the present disclosure. The naming of the compounds does not exclude any tautomers.
[0174] The present disclosure also includes isotopically labeled compounds of the present disclosure that are identical to those described herein, but in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.
[0175] Unless otherwise stated, when a position is specifically designated as deuterium (D), the position is understood to have deuterium (i.e., at least 10% deuterium incorporation) at least 1000 times greater than the natural abundance of deuterium (which is 0.015%). The natural abundance of the compound in the example may be at least 1000 times greater than deuterium, at least 2000 times greater than deuterium, at least 3000 times greater than deuterium, at least 4000 times greater than deuterium, at least 5000 times greater than deuterium, at least 6000 times greater than deuterium, or more. The present disclosure also includes various deuterated forms of compounds of formula (I), formula (I'), and formula (II). Each available hydrogen atom connected to a carbon atom may be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of compounds of formula (I), formula (I'), and formula (II) with reference to relevant literature. Commercially available deuterated starting materials can be used to prepare deuterated forms of compounds of formula (I), formula (I'), and formula (II), or they can be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide, and deuterated methyl iodide.
[0176] The present disclosure also provides a method for preparing a dsRNA or a pharmaceutical composition, which comprises: synthesizing the dsRNA or the pharmaceutical composition described in the present disclosure.
[0177] The present disclosure introduces the full text of WO2014025805A1, WO2022028462A1 and WO2023274395A1.
[0178] Explanation of terms
[0179] As used herein, the term "comprising" or "including" means including the stated elements, integers or steps, but does not exclude any other elements, integers or steps. In this article, when the term "comprising" or "including" is used, unless otherwise specified, the situation consisting of the stated elements, integers or steps is also covered. For example, when referring to "comprising" a specific sequence, it is also intended to cover the situation consisting of the specific sequence.
[0180] Unless otherwise indicated, "optionally", "optional", "optional" or "optional" means that the event or circumstance described subsequently may but need not occur, and the description includes occasions where the event or circumstance occurs or does not occur. For example, "optionally, R1 and R2 are directly connected to form a ring" means that R1 and R2 are directly connected to form a ring, which may occur but need not exist, and the description includes the situation where R1 and R2 are directly connected to form a ring and the situation where R1 and R2 do not form a ring.
[0181] The terms "about" and "approximately" refer to values within an acceptable error range for a specific value determined by a person of ordinary skill in the art, which value depends in part on how it is measured or determined (i.e., the limits of the measurement system). For example, "about" can mean a standard deviation within or exceeding 1. Alternatively, "about" or "substantially including" can mean a range of up to 20%, such as between 1% and 15%, between 1% and 10%, between 1% and 5%, between 0.5% and 5%, between 0.5% and 1%, and in this disclosure, each case in which a number or numerical range is preceded by the term "about" also includes embodiments of the given number. Unless otherwise stated, when a specific value appears in the present application and claims, the meaning of "about" or "substantially including" should be assumed to be within an acceptable error range for that specific value.
[0182] Unless otherwise specified, the "compound", "chemical modification", "ligand", "dsRNA", "nucleic acid" and "RNAi" of the present disclosure may independently exist in the form of salt, mixed salt or non-salt (e.g., free acid or free base). When it exists in the form of salt or mixed salt, it may be a pharmaceutically acceptable salt.
[0183] "Pharmaceutically acceptable salt" may be selected from inorganic salts or organic salts, and may also include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0184] "Pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, and the like; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, caprylates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamates, pyroglutamates, aspartates, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbates, salicylates, 4-aminosalicylates, naphthalene disulfonates, and the like. These salts can be prepared by methods known in the art.
[0185] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. In some embodiments, the inorganic salt is an ammonium salt, sodium salt, potassium salt, calcium salt, and magnesium salt, and in some embodiments, a sodium salt. Salts derived from organic bases include, but are not limited to, the following salts: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. In some embodiments, organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.
[0186] "Alkyl" refers to a saturated aliphatic hydrocarbon group, such as straight and branched chain groups (C1-C12) containing 1 to 30 carbon atoms. 30 The term "alkyl" refers to an alkyl group having 1 to 6 carbon atoms (C1-C6 alkyl), or an alkyl group having 1 to 3 carbon atoms (C1-C3 alkyl). Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, and various branched isomers thereof.
[0187] The term "alkenyl" refers to a hydrocarbon group containing at least one double bond. Non-limiting examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl or 2-butenyl and their various branched chain isomers.
[0188] The term "alkynyl" refers to a hydrocarbon group containing at least one triple bond. Non-limiting examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl or 2-butynyl and their various branched chain isomers.
[0189] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy.
[0190] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 6 carbon atoms, more preferably 5-6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, etc.; polycyclic cycloalkyls include spirocyclic, cyclocyclic and bridged cycloalkyls.
[0191] The heterocycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a heterocycloalkyl, non-limiting examples of which include:
[0192] wait.
[0193] Heterocycloalkyl may be optionally substituted or unsubstituted, and when substituted, the substituents are in some embodiments selected from one or more of the following groups, which are independently selected from halogen, deuterium, hydroxyl, oxo, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 The cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl may be optionally substituted by one or more groups selected from halogen, deuterium, hydroxy, oxo, nitro and cyano.
[0194] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, selected from 6- to 12-membered in some embodiments, such as phenyl and naphthyl. The aryl ring may be fused to a heteroaryl, heterocycloalkyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:
[0195]
[0196] The aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate, preferably phenyl.
[0197] The term "condensed ring aryl" can be an unsaturated aromatic condensed ring structure containing 8-14 ring atoms formed by two or more ring structures sharing two adjacent atoms, preferably 8-12 ring atoms. For example, it includes all unsaturated condensed ring aryl groups, such as naphthalene, phenanthrene, etc., and also includes partially saturated condensed ring aryl groups, such as benzo 3-8 membered saturated monocyclic cycloalkyl, benzo 3-8 membered partially saturated monocyclic cycloalkyl. "Condensed aromatic ring" refers to the ring system in the condensed ring aryl group. Specific examples of condensed ring aryl groups include 2,3-dihydro-1H-indenyl, 1H-indenyl, 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, etc.
[0198] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 5 to 12 members, such as imidazolyl, furanyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidyl, thiadiazole, pyrazinyl, etc., preferably imidazolyl, pyrazolyl, pyrimidyl or thiazolyl; more preferably pyrazolyl or thiazolyl. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. "Heteroaromatic ring" refers to the ring system in a heteroaryl group. Non-limiting examples of heteroaryl include:
[0199]
[0200] Heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are in some embodiments selected from one or more of the following groups independently selected from halogen, deuterium, hydroxyl, oxo, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6Alkynyloxy, C 3-6 Cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 The cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl is optionally substituted by one or more groups selected from halogen, deuterium, hydroxy, oxo, nitro, cyano.
[0201] The term "alkylamino" refers to a group having the structure -NH(C1-C12 alkyl).
[0202] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0203] The term "hydroxy" refers to an -OH group.
[0204] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0205] The term "haloalkyl" refers to an alkyl group substituted with a halogen, wherein alkyl is as defined above.
[0206] The term "haloalkoxy" refers to an alkoxy group substituted with a halogen, wherein alkoxy is as defined above.
[0207] The term "cyano" refers to -CN.
[0208] The term "nitro" refers to -NO2.
[0209] The term "oxo" refers to a =0 group, for example, a carbon atom is connected to an oxygen atom via a double bond, wherein a ketone or aldehyde group is formed.
[0210] The term "amino" refers to -NH2.
[0211] The term "carboxy" refers to -C(O)OH.
[0212] The terms "blunt end" or "blunt terminus" are used interchangeably and refer to the absence of unpaired nucleotides or nucleotide analogs at a given end of a dsRNA, i.e., no nucleotide overhangs. In most cases, a dsRNA with both ends blunt-ended will be double-stranded throughout its entire length.
[0213] In the context of the present disclosure, the phosphodiester group or the phosphodiester group with modification in each modification group can be replaced by any group that can achieve the connection with the adjacent nucleotide.
[0214] "Substitution" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in a group are replaced independently by a corresponding number of substituents. When the substituent is keto or oxo (i.e., =O), two (2) hydrogen atoms on the atom are replaced.
[0215] The term "linked", when referring to the connection between two molecules, means that the two molecules are connected by a covalent bond or the two molecules are associated via a non-covalent bond (eg, a hydrogen bond or an ionic bond), including direct connection and indirect connection.
[0216] The term "directly linked" refers to a first compound or group being linked to a second compound or group without any intervening atoms or groups of atoms.
[0217] The term "indirectly linked" means that a first compound or group is linked to a second compound or group through an intermediate group, compound or molecule (eg, a linking group).
[0218] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0219] "Pharmaceutically acceptable excipients" include, but are not limited to, any adjuvant, carrier, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the U.S. Food and Drug Administration (FDA) for use by humans or domestic animals.
[0220] As used herein, the term "inhibition" can be used interchangeably with "reduction", "silence", "downregulation", "suppression" and other similar terms, and includes inhibition at any level. Inhibition can be assessed by the reduction of the absolute or relative level of one or more of these variables compared to the control level. The control level can be any type of control level used in the art, such as baseline level before administration or the level determined from a similar untreated or controlled subject, cell, or sample (such as only buffer control or inert agent control). For example, the remaining expression of mRNA can be used to characterize the degree of inhibition of dsRNA on target gene expression, such as the remaining expression of mRNA is not higher than 99%, not higher than 95%, not higher than 90%, not higher than 85%, not higher than 80%, not higher than 75%, not higher than 70%, not higher than 65%, not higher than 60%, not higher than 55%, not higher than 50%, not higher than 45%, not higher than 40%, not higher than 35%, not higher than 30%, not higher than 25%, not higher than 20%, not higher than 15%, or not higher than 10%. The inhibition rate of target gene expression can be measured by Luciferase Assay System was used for detection. The chemiluminescence values of Firefly and Renilla were read respectively, and the relative value Ratio = Ren / Fir was calculated. The inhibition rate (%) = 1-(Ratio + dsRNA / Ratioreporter only) * 100%. In the present disclosure, the remaining mRNA expression ratio (or remaining activity %) = 100% - inhibition rate (%).
[0221] An "effective amount" or "effective dose" encompasses an amount sufficient to ameliorate or prevent the symptoms or symptoms of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's general health, the method, route and dosage of administration, and the severity of side effects. An effective amount may be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
[0222] As used herein, "subject," "patient," "subject," or "individual" are used interchangeably and include humans or non-human animals, such as mammals, such as humans or monkeys.
[0223] Unless otherwise specified, in the context of this disclosure, the terms "angiotensinogen" and "AGT" are used interchangeably herein. AGT is also known as SERPINA8 and ANHU. AGT includes but is not limited to human AGT, cynomolgus monkey AGT, mouse AGT, rat AGT, and its amino acid and complete coding sequence, mRNA sequence are easily obtained using publicly available databases, such as GenBank, UniProt, OMIM and the Macaca genome project website.
[0224] The term "AGT" also refers to naturally occurring DNA sequence variations of the AGT gene, such as single nucleotide polymorphisms (SNPs) in the AGT gene. Exemplary SNPs can be found in the dbSNP database.
[0225] The term "target sequence" refers to a continuous portion of the nucleotide sequence of the mRNA molecule formed during transcription of the AGT gene, including mRNA that is an RNA processing product of the primary transcription product. The targeted portion of the target sequence should be long enough to serve as a substrate for iRNA-directed cleavage. In one embodiment, the target sequence is within the protein coding region of AGT.
[0226] The term "dsRNA" refers to a double-stranded RNA molecule capable of RNA interference, comprising a sense strand and an antisense strand.
[0227] As used herein, the sense strand (also referred to as SS, SS strand or positive strand) refers to a strand comprising a sequence identical or substantially identical to a target mRNA sequence; the antisense strand (also referred to as AS or AS strand) refers to a strand having a sequence complementary to a target mRNA sequence.
[0228] In the context of describing the sense strand of the dsRNA described herein, the term "the nucleotide sequence of SEQ ID NO: 1 differs by no more than 3 nucleotide sequences of at least 15 consecutive nucleotides" is intended to indicate that the sense strand of the dsRNA described herein comprises, for example, at least 15 consecutive nucleotides of SEQ ID NO: 1, or differs by no more than 3 nucleotide sequences, optionally, differs by no more than 2 nucleotide sequences, optionally, differs by 1 nucleotide sequence from at least 15 consecutive nucleotides of SEQ ID NO: 1. Other similar descriptions should also be understood accordingly.
[0229] Unless otherwise specified, in the context of the present disclosure, "G", "C", "A", "T" and "U" represent nucleotides, which respectively include guanine, cytosine, adenine, thymidine and uracil bases. The lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleoside; the lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a fluorinated-modified nucleoside; the lowercase letter s indicates that the two nucleosides adjacent to the left and right of the letter s or the nucleoside and the chemical modification are connected by a thiophosphate diester group.
[0230] As used in the present disclosure, the term "2'-fluoro (2'-F) modified nucleoside" refers to a nucleoside in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is substituted by fluorine, and "non-fluorinated modified nucleotide" refers to a nucleoside or nucleoside analog in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is substituted by a non-fluorine group.
[0231] As used in the present disclosure, the term "2'-methoxy (2'-OMe) modified nucleoside" refers to a nucleoside in which the 2'-hydroxyl group of the ribose group is replaced by a methoxy group.
[0232] In the context of the present disclosure, unless otherwise specified, the structures of the 2'-methoxy modified nucleosides, 2'-fluoro modified nucleosides, phosphorothioate diester groups, phosphodiester groups, (-)hmpNA(C) and L96 are shown in the following table. When the dsRNA of the present disclosure exists in a salt form, such as a sodium salt form, the salt form or ion form corresponding to the structure in the following table is also within the protection scope of the present disclosure:
[0233]
[0234] In the context of the present disclosure, a "nucleotide difference" between a nucleotide sequence and another nucleotide sequence means that the base type of the nucleotide at the same position in the former is changed compared with the latter. For example, when a nucleotide base in the latter is A, and the corresponding nucleotide base at the same position in the former is U, C, G or T, it is considered that there is a nucleotide difference at that position between the two nucleotide sequences. In some embodiments, when a nucleotide at the original position is replaced by an abasic nucleotide or its equivalent, it can also be considered that a nucleotide difference occurs at that position.
[0235] As used herein, the terms "complementary" or "reverse complement" are used interchangeably and have the meanings known to those skilled in the art, i.e., in a double-stranded nucleic acid molecule, the bases of one chain are paired with the bases on the other chain in a complementary manner. In DNA, the purine base adenine (A) is always paired with the pyrimidine base thymine (or uracil in RNA); the purine base guanine is always paired with the pyrimidine base cytosine. Each base pair includes a purine and a pyrimidine. When adenine on one chain is always paired with thymine (or uracil) on the other chain, and guanine is always paired with cytosine, the two chains are considered to be complementary to each other, and the sequence of the chain can be inferred from the sequence of its complementary chain. Accordingly, "mismatch" means in the art that the bases at corresponding positions in a double-stranded nucleic acid are not paired in a complementary form.
[0236] The term "chemical modification" or "modification" includes all changes in the nucleotide by chemical means, such as the addition or removal of a chemical moiety, or the substitution of one chemical moiety for another.
[0237] The term "base" includes any known DNA and RNA base, base analogs, such as purine or pyrimidine, which also includes the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine and natural analogs. Base analogs can also be universal bases.
[0238] The terms "blunt end" or "blunt terminus" are used interchangeably and refer to the absence of unpaired nucleotides or nucleotide analogs at a given end of a dsRNA, i.e., no nucleotide overhangs. In most cases, a dsRNA with both ends blunt-ended will be double-stranded throughout its entire length.
[0239] The dsRNA provided by the present disclosure can be obtained by conventional preparation methods in the art (e.g., solid phase synthesis and liquid phase synthesis methods). Among them, solid phase synthesis has commercial customization services. The modified nucleotide groups can be introduced into the dsRNA described in the present disclosure by using nucleoside monomers with corresponding modifications. Methods for preparing nucleoside monomers with corresponding modifications and methods for introducing modified nucleotide groups into dsRNA are also well known to those skilled in the art. DETAILED DESCRIPTION
[0240] The present disclosure is further described below in conjunction with examples, but these examples are not intended to limit the scope of the present disclosure. Experimental methods in the examples of the present disclosure that do not specify specific conditions are generally performed under conventional conditions or under conditions recommended by raw material or commodity manufacturers. Reagents that do not specify specific sources can be obtained from any supplier of molecular biology reagents with quality / purity for molecular biology applications.
[0241] Example 1: Synthesis of dsRNA
[0242] 1. Make your own resin with a carrier
[0243] 2. Using the resin with L96 as the starting point, connect the nucleoside monomers one by one from the 3'-5' direction according to the nucleotide arrangement order. Each connection of a nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization. Among them, L96 and 036 can be directly cited from the prior patents. L96 is prepared according to the method described in patent application WO2014025805A1, and (-)hmpNA(C) is prepared according to the method described in patent application WO2022028462A1. The prepared dsRNA has the sense strand and antisense strand shown in Table 1:
[0244] Table 1. dsRNAs of the present disclosure
[0245]
[0246]
[0247]
[0248] In Table 1, in the same nucleic acid sequence, from left to right in the direction from 5' to 3', G, C, A, and U represent nucleosides with guanine, cytosine, adenine, and uracil, respectively. The sequence represents the direction from 5' to 3' from left to right. The lowercase letter m indicates that the nucleoside adjacent to the left of the letter m is a 2'-methoxy-modified nucleoside; the lowercase letter f indicates that the nucleoside adjacent to the left of the letter f is a 2'-fluoro-modified nucleoside; the structures of (-)hmpNA(C) and L96 are shown in the following table, and the lowercase letter s indicates that the two nucleosides adjacent to the letter s or the ligand are connected by a thiophosphate diester group. Unless otherwise specified, the two adjacent nucleosides are connected by a phosphodiester group. Unless otherwise specified, the 3' position of the first nucleotide at the 3' end of each chain is a hydroxyl group; the 5' position of the first nucleotide at the 5' end of each chain is a hydroxyl group.
[0249] The structures of the 2'-methoxy modified nucleosides, 2'-fluoro modified nucleosides, thiophosphate diester groups, phosphodiester groups, (-)hmpNA(C) and L96 are shown in the following table. When the dsRNA of the present invention exists in the form of a salt, for example, in the form of a sodium salt, the salt forms corresponding to the structures in the following table are also within the scope of protection of the present invention:
[0250]
[0251]
[0252] Example 2. On-target activity against AGT target
[0253] In vitro molecular level simulation on-target activity screening was performed using 9 concentration gradients in HEK293A cells.
[0254] The target sequence corresponding to the siRNA was constructed with the AGT gene and inserted into the psiCHECK-2 plasmid. The plasmid contains the Renilla luciferase gene and the firefly luciferase gene. As a dual reporter gene system, the target sequence of the siRNA is inserted into the 3'UTR region of the Renilla luciferase gene. The activity of the siRNA against the target sequence can be reflected by the detection of the expression of the Renilla luciferase calibrated with the firefly luciferase, and the detection uses the Dual-Luciferase Reporter Assay System (Promega, E2940).
[0255] HEK293A cells were cultured in DMEM high-glucose medium containing 10% fetal bovine serum at 37°C and 5% CO2. 24 h before transfection, HEK293A cells were seeded in 96-well plates at a seeding density of 12 × 10 3 cells per well, 100 μL of culture medium per well.
[0256] According to the instructions, Lipofectamine2000 (ThermoFisher, 11668019) was used to co-transfect the cells with siRNA and the corresponding plasmid, and 0.2 μL of Lipofectamine2000 was used per well. The amount of plasmid transfection was 20 ng per well. For the target sequence plasmid, 9 concentration points were set for siRNA, and the final concentration of the highest concentration point was 20 nM, 4-fold gradient dilution, 20 nM, 5 nM, 1.25 nM, 0.3125 nM, 0.0781 nM, 0.0195 nM, 0.0049 nM, 0.0012 nM, 0.0003 nM. 24 h after transfection, the Dual-Luciferase Reporter Assay System (Promega, E2940) was used to detect the target level.
[0257] The experimental materials and instruments are detailed in Tables 2 and 3. The dilution process is shown in Table 4. The results are shown in Table 5.
[0258] Psi-CHECK plasmid was purchased from Sangon Biotech (Shanghai) Co., Ltd.
[0259] Table 2. Psi-CHECK experimental consumables and reagents
[0260]
[0261] Table 3. Psi-CHECK test equipment
[0262]
[0263] Table 4. Sample dilution scheme for multiple concentrations
[0264]
[0265]
[0266] Table 5. Psi-CHECK on-target activity screening results
[0267]
[0268] The above results indicate that TJR101202 has a high level of on-target inhibitory activity against the AGT gene in the psiCHECK system.
[0269] Example 3: Inhibitory activity of AGT at multiple concentrations in human hepatoma cell line (Hep3B)
[0270] A dose response experiment was performed using a 7-concentration gradient in a human hepatoma cell line (Hep3B).
[0271] 24h before transfection, Hep3B cells were seeded in 96-well plates at approximately 20,000 cells / well, with 100 μL of culture medium per well. During transfection, refer to the product manual and use Lipofectamine RNAi MAX (ThermoFisher, 13778150) to transfect the samples. The final concentrations of the gradient transfection of the samples were 10, 2, 0.4, 0.08, 0.016, 0.0032 and 0.00064 nM. After 24 hours of treatment, total cell RNA was extracted using the high-throughput cell RNA extraction kit FG0417-L / FG0418-XL, magnetic bead method) and RNA reverse transcription experiments (Takara PrimeScript TM The mRNA level of human AGT was determined by using the II 1st Strand cDNA Synthesis Kit (6210A) and quantitative real-time PCR (ThermoFisher TaqMan Fast Advanced Master Mix (4444964)), and the mRNA level of human AGT was corrected according to the level of the GAPDH internal reference gene.
[0272] The instruments involved in this experiment are shown in Table 6.
[0273] Table 6. Experimental instruments
[0274]
[0275]
[0276] Among them, in the real-time quantitative PCR detection, a probe Q-PCR detection experiment was used, and its primer information is shown in Table 7.
[0277] Table 7. Taqman primer information table
[0278]
[0279] Result analysis method
[0280] After the Q-PCR test is completed, the corresponding Ct value is obtained according to the threshold value automatically set by the system. The expression of a gene can be relatively quantified by comparing the Ct values: Comparative Ct refers to calculating the difference in gene expression by the difference between the Ct value of the internal reference gene, also known as 2 -△△Ct , △△Ct=[(Ct experimental group target gene-Ct experimental group internal reference)-(Ct control group target gene-Ct control group internal reference)]. Inhibition rate (%)=(1-remaining amount of target gene expression)*100%.
[0281] The results were expressed as the remaining percentage of human AGT mRNA expression relative to that of cells treated with control samples. The IC 50 The results are shown in Table 8.
[0282] Table 8. Inhibitory activity against human AGT in Hep3B cells
[0283]
[0284] From the data in Table 8, we can see that:
[0285] TJR100283 has better inhibitory activity against AGT than TJR100286, TJR100290, TJR100291, TJR100292 and TJR100293. The sequences of these samples were transformed by mutating the first base at the 5' end of the TJR100283 sequence, shifting the bases left and right, etc. The results showed that TJR100283 exhibited better inhibitory activity against AGT, and the base changes weakened the inhibitory activity against AGT.
[0286] Example 4: Inhibitory activity of AGT at multiple concentrations in monkey primary hepatocytes (PCH)
[0287] Dose response experiments were performed in primary monkey hepatocytes (PCH) using a 7-concentration gradient.
[0288] During transfection, refer to the product manual and use Lipofectamine RNAiMAX (ThermoFisher, 13778150) to transfect the sample. The final gradient concentration of the sample transfection is 10, 2, 0.4, 0.08, 0.016, 0.0032 and 0.00064nM. Mix the RNAiMAX diluted with Opti-MEM I and the sample in equal volumes, incubate at room temperature for 15 minutes, add 10 μL per well to a 96-well plate, and then add 90 μL of revived frozen PCH cell suspension (6.7E5 cells / mL) to each well. Collect cells 24 hours after transfection and extract total cell RNA using RNeasy96Kit (Qiagen-74182). Refer to the instructions of the reverse transcription kit (Tiangen, KR106) and add random primers for reverse transcription into cDNA. The qPCR method was used to detect the AGT mRNA level in the sample, and the monkey AGT mRNA level was corrected according to the GAPDH internal reference gene level. The probe primer sequence information is shown in Table 9.
[0289] The expression level of target AGT mRNA in each sample was calculated by ΔΔCt relative quantitative method. The relative expression of target gene was calculated by 2 -ΔΔCT It indicates that the calculation formula refers to Example 3.
[0290] IC was calculated using GraphPad Prism software (four parameter logistic equations). 50 The results are shown in Table 10.
[0291] Table 9. Taqman probe primer information table
[0292]
[0293] Table 10. Inhibitory activity of 7 concentrations on monkey AGT in PCH cells
[0294]
[0295] The results showed that the activity of TJR100283 was significantly better than that of TJR100292, TJR100293 and TJR100295, indicating that the TJR100283 sequence itself has a strong inhibitory activity against AGT.
[0296] Example 5: On-target activity against AGT target
[0297] In vitro molecular level simulation on-target activity screening was performed using 9 concentration gradients in HEK293A cells. The experimental scheme, compound dilution method, reagents, consumables and instruments used in this example refer to Example 2.
[0298] Table 11. Psi-CHECK on-target activity screening results
[0299]
[0300] The above results indicate that TJR101202 has a high level of on-target inhibitory activity against the AGT gene in the psiCHECK system, which is significantly better than TJR103179.
Claims
1. A double-stranded ribonucleic acid (dsRNA) comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise consecutive nucleotides in a 5' to 3' direction, wherein The nucleotides at positions 7, 8 and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides; The nucleotides at positions 2, 6, 12, 14 and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides; The nucleotide position at position 7 of the antisense strand comprises a chemical modification represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof: The chemical modification represented by the formula (I) is selected from any of the following structures: B is the base of the antisense strand when the 7th nucleotide in the 5' region is unmodified; The dsRNA also includes a ligand conjugated thereto, and the 3' end of the sense strand of the dsRNA is conjugated to the ligand, and the ligand has the following structure or a pharmaceutically acceptable salt thereof, The dsRNA inhibits the expression of angiotensinogen (AGT).
2. The dsRNA according to claim 1, wherein At least one phosphate group in the sense strand and / or antisense strand is a phosphate group having a modified group, preferably a phosphorothioate group, and more preferably a phosphorothioate diester group.
3. The dsRNA according to claim 2, wherein The sense strand and / or antisense strand comprises a plurality of phosphorothioate diester groups, wherein the phosphorothioate diester groups are present in: between the first nucleotide and the second nucleotide at the 5' end of the sense strand; and, between the second nucleotide and the third nucleotide at the 5' end of the sense strand; and, between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; and, between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; and, between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and, Between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
4. The dsRNA according to any one of claims 1 to 3, wherein The sense strand comprises the nucleotide sequence shown in SEQ ID NO:1, and the antisense strand comprises the nucleotide sequence shown in SEQ ID NO:
2.
5. The dsRNA of claim 4, wherein The sense strand is the nucleotide sequence shown in SEQ ID NO:1, and the antisense strand is the nucleotide sequence shown in SEQ ID NO:
2.
6. A pharmaceutical composition comprising the dsRNA according to any one of claims 1 to 5; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
7. A vector comprising the dsRNA according to any one of claims 1 to 5.
8. A cell comprising the dsRNA according to any one of claims 1 to 5, or the vector according to claim 6.
9. Use of the dsRNA according to any one of claims 1 to 5, the pharmaceutical composition according to claim 6, the vector according to claim 7, or the cell according to claim 8 in the preparation of a medicament; the medicament is used for preventing and / or treating hypertension.
10. A kit comprising the dsRNA of any one of claims 1 to 5, the pharmaceutical composition of claim 6, the vector of claim 7, or the cell of claim 8.
11. A method for preparing a dsRNA or a pharmaceutical composition, comprising: Synthesize the dsRNA according to any one of claims 1 to 5 or the pharmaceutical composition according to claim 6.
